[Autoantibodies related to interferon therapy in chronic hepatitis B may affect the therapeutic response to interferon].
We have evaluated the problem of autoantibodies such as antinuclear antibodies (ANA), smooth muscle antibody (SMA) and antibodies to thyroid microsomal (TMA) and to thyroglobulin (TGA) related to interferon therapy in 27 patients with chronic hepatitis B. Anti-interferon antibody was also studied by Western blot method. Eight patients had ANA and 2 had SMA during interferon therapy. However, 6 of the 8 patients were ANA positive and one of the 2 was SMA positive prior to interferon treatment. No patients developed TMA, TGA or anti-interferon antibody. Eight (29.6%) of the 27 patients had clearance of both DNA polymerase and HBeAg and persistent normalization in alanine aminotransferase levels with interferon therapy. Seven of the 8 responders developed none of the autoantibodies related to interferon therapy. These results suggest that the presence of ANA or SMA during treatment may affect the therapeutic response to interferon.
Okuno
T
T
Department of Internal Medicine, Akashi Municipal Hospital.
Shindo
M
M
Arai
K
K
Matsumoto
M
M
Takeda
M
M
Kashima
K
K
D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000378:metabolism; D001323:Autoantibodies / Q000378:metabolism*; D002908:Chronic Disease; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000276:immunology
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D007372:Interferons